Publication | Open Access

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Gastrointestinal OncologyMedicinePharmacologyPathologyPharmacotherapyCancer TreatmentOncologyRadiation OncologyMolecular Oncology